Bioray Biotech Co., Ltd
Bioray Biotech Co., Ltd engages in the production, research, and sells health foods, immune cell products, and precision testing services in Taiwan. It offers health care products, including various functional foods and supplements; medicinal fungi; immune cell products; and precision medicine services, such as immunology, cell division, and specialized laboratory testing. The company is also inv… Read more
Bioray Biotech Co., Ltd (7561) - Total Assets
Latest total assets as of June 2025: NT$523.97 Million TWD
Based on the latest financial reports, Bioray Biotech Co., Ltd (7561) holds total assets worth NT$523.97 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioray Biotech Co., Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Bioray Biotech Co., Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioray Biotech Co., Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioray Biotech Co., Ltd's total assets of NT$523.97 Million consist of 56.2% current assets and 43.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 32.8% |
| Accounts Receivable | NT$54.73 Million | 10.1% |
| Inventory | NT$46.27 Million | 8.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$861.00K | 0.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Bioray Biotech Co., Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioray Biotech Co., Ltd's current assets represent 56.2% of total assets in 2024, a decrease from 58.0% in 2019.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, down from 42.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Bioray Biotech Co., Ltd Competitors by Total Assets
Key competitors of Bioray Biotech Co., Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Bioray Biotech Co., Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bioray Biotech Co., Ltd generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Bioray Biotech Co., Ltd generates $ 0.18 in net profit.
Bioray Biotech Co., Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.15 | 3.36 | 3.18 |
| Quick Ratio | 5.80 | 2.70 | 2.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$253.05 Million | NT$ 205.42 Million | NT$ 177.72 Million |
Bioray Biotech Co., Ltd - Advanced Valuation Insights
This section examines the relationship between Bioray Biotech Co., Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | NT$543.63 Million |
| Market Capitalization | $10.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioray Biotech Co., Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bioray Biotech Co., Ltd's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bioray Biotech Co., Ltd (2019–2024)
The table below shows the annual total assets of Bioray Biotech Co., Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$543.63 Million | +0.18% |
| 2023-12-31 | NT$542.65 Million | -9.35% |
| 2022-12-31 | NT$598.63 Million | +28.41% |
| 2021-12-31 | NT$466.18 Million | -2.02% |
| 2020-12-31 | NT$475.80 Million | -4.79% |
| 2019-12-31 | NT$499.74 Million | -- |